UCB Pharma GmbH
Schwarz Pharma AG: FDA Approves SCHWARZ PHARMA’s Neupro (Rotigotine Transdermal System)
SCHWARZ PHARMA AG / Regulatory Approval Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- FDA Approves SCHWARZ PHARMA's Neupro (Rotigotine Transdermal System) for the Treatment of early-stage Parkinson's Disease in USA SCHWARZ PHARMA announced today that the U.S. Food and Drug Administration (FDA) has approved Neupro® (Rotigotine Transdermal System) for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease (PD). Neupro is the first once daily, continuous delivery transdermal dopamine agonist for early stage Parkinson's disease. SCHWARZ PHARMA will launch the product in the U.S. within the next weeks. You find more information on the internet: www.schwarzpharma.com SCHWARZ PHARMA AG is listed in the Prime Standard of the Frankfurter Wertpapierbörse (Frankfurt stock exchange) and member in the German stock index SDAX Security code no. 722 190 / ISIN no.: DE 0007221905 SCHWARZ PHARMA AG Alfred-Nobel-Str. 10 40789 Monheim Germany Corporate Communications: Antje Witte, Tel: +49 2173 48 1866 --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: 'This is an important step forward for the patients suffering from Parkinson's disease. Following approval and launch within Europe, Neupro will now be available for patients in the USA', comments Iris Loew-Friedrich, MD, PhD, CSO SCHWARZ PHARMA AG. 'We intend to submit a supplemental New Drug Application for the treatment of advanced Parkinson's disease to the FDA by the end of 2007.' Contact: Corporate Communications: Antje Witte, Tel: +49 2173 48 1866; Bettina Ellinghorst, Tel.: +49 2173 48 2329 DGAP 10.05.2007 ---------------------------------------------------------------------- Language: English Issuer: SCHWARZ PHARMA AG Alfred-Nobel-Str. 10 40789 Monheim Deutschland Phone: +49 2173 48 1866 Fax: +49 2173 48 1856 E-mail: antje.witte@schwarzpharma.com www: www.schwarzpharma.com ISIN: DE0007221905 WKN: 722190 Indices: SDAX, MIDCAP, PRIMEALL, CLASSICALLSHARE, CDAX, HDAX, GEX Listed: Amtlicher Markt in Frankfurt (Prime Standard), Düsseldorf; Freiverkehr in Berlin-Bremen, Hannover, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden